Overview

Cabergoline Reduces OHSS

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
0
Participant gender:
Female
Summary
The present study was designed to provide clinical confirmation of Cb2's value as a new approach in the prevention of increased vascular permeability and hemoconcentration, both signs of OHSS in humans, and in order to explore its mechanism of action. To this end, a prospective, randomized, placebo-controlled study was designed in which Cb2 was employed in women at risk of OHSS after gonadotropin administration for ART. Simultaneously, ovarian perfusion was assessed in these patients using MR pharmacokinetic modeling.
Phase:
Phase 3
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Instituto Valenciano de Infertilidad, IVI VALENCIA
Treatments:
Cabergoline
Dopamine
Dopamine Agonists
Criteria
Inclusion Criteria:

- 18 - 35 years old healthy women, with risk of developing OHSS.

Exclusion Criteria:

- No risk of developing OHSS; < 20 oocytes retrieved.